The Asia Pacific Epigenetics Market would witness market growth of 15.2% CAGR during the forecast period (2022-2028).
DNA methylation, histone methylation, and acetone methylation are some of the most common epigenetic technologies. Strong correlations between DNA methylation and aging have been discovered through research. The International Human Epigenome Consortium, the National Cancer Institute (NCI), and the National Institute of Health (NIH) are all affecting the market in a good way by providing financial support for epigenetics research and development. Moreover, the growing emphasis on studying epigenetic changes at the genetic and molecular level, as well as the development of epigenetics-based medicinal treatments, is likely to have a favorable impact on research funding.
The epigenetics market is primarily driven by technological breakthroughs in the field of epigenetics. In comparison to typical microarrays, epigenetics-based assays are extremely useful and advantageous due to advantages such as the requirement for a low concentration of input material and the lack of experimental bias in microarrays. Advanced epigenetic tools and sequencing platforms have been the subject of research.
Major trends in the APAC region are increased awareness of epigenetics, increased penetration of important players in growing Asia-Pacific countries, and expansion of research and clinical infrastructure. Due to increased disposable income, significant unmet clinical requirements of patients, rising knowledge of early diagnosis, and availability of efficient treatment in emerging nations such as India and China, the market is likely to flourish in the upcoming years. In addition, an increase in instances of various types of malignancies in this region is the prominent growth catalyst for the regional market.
Moreover, the regional market has witnessed increased disposable income, significant unmet clinical needs of patients, growing awareness of early diagnosis, and availability of suitable treatment in emerging nations such as India and China. Because of the increased cases of various forms of malignancies in this region, Asia Pacific is the most promising region for industry players. Market growth is expected to be aided by the growing geriatric population.
The China market dominated the Asia Pacific Epigenetics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $232.4 Million by 2028. The Japan market is anticipated to grow at a CAGR of 14.5% during (2022 - 2028). Additionally, The India market would showcase a CAGR of 15.9% during (2022 - 2028).
Based on Application, the market is segmented into Oncology and Non-Oncology. Based on Product, the market is segmented into Kits, Reagents, Enzymes, and Instruments. Based on End User , the market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Contract Research Organizations. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Epigenetics Market is Projected to reach USD 2.9 Billion by 2028, at a CAGR of 14.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abcam plc, Agilent Technologies, Inc., Hologic, Inc., Illumina, Inc., Merck Group, PerkinElmer, Inc., Qiagen N.V., Thermo Fisher Scientific, Inc., Zymo Research, and Active Motif, Inc.
By Application
By Product
By End User
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 